Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
- Published In:
- Diabetes care, 38(6), 951-3 (2015)
- Authors:
- Azoulay, Laurent
- Database ID:
- RPEP-02578
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02578APA
Azoulay, Laurent. (2015). Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.. Diabetes care, 38(6), 951-3. https://doi.org/10.2337/dc15-0347
MLA
Azoulay, Laurent. "Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.." Diabetes care, 2015. https://doi.org/10.2337/dc15-0347
RethinkPeptides
RethinkPeptides Research Database. "Incretin-based drugs and adverse pancreatic events: almost a..." RPEP-02578. Retrieved from https://rethinkpeptides.com/research/azoulay-2015-incretinbased-drugs-and-adverse
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.